Previous 10 | Next 10 |
2024-03-15 09:18:40 ET More on SELLAS Life Sciences Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Sellas Life Sciences gains after leukemia therapy gets FDA fast track status Read the full article on Seeking Alpha For furthe...
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today...
VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is issuing the following news release as a result of a continuous disclosure review by the British Columbia Securities Comm...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today...
- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR) achieved after three months of treatment with duration of eight months and one year survival at the latest assessment - - First time achievemen...
VANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a trilateral cooperation agreement with the Interprovincial Federation of Shuar Centers (“FICS...
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announce...
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announce...
VANCOUVER, British Columbia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a corporate update including the commencement of the 2024 drilling program at its Warintza Project (&...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in ...
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - ...
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients with ASXL1 Mutation in the SLS009 30mg BIW Cohort to Date, Al...